Pharmaceutical Research Laboratories, Toray Industries, Inc, Kanagawa, Japan.
Gastroenterology. 2013 Aug;145(2):447-55.e1-4. doi: 10.1053/j.gastro.2013.05.007. Epub 2013 May 11.
BACKGROUND & AIMS: Hepatitis C virus (HCV) infection is a major cause of liver cancer, so strategies to prevent infection are needed. A system for cell culture of infectious HCV particles (HCVcc) has recently been established; the inactivated HCVcc particles might be used as antigens in vaccine development. We aimed to confirm the potential of HCVcc as an HCV particle vaccine.
HCVcc derived from the J6/JFH-1 chimeric genome was purified from cultured cells by ultrafiltration and ultracentrifugation purification steps. Purified HCV particles were inactivated and injected into female BALB/c mice with adjuvant. Sera from immunized mice were collected and their ability to neutralize HCV was examined in naive Huh7.5.1 cells and urokinase-type plasminogen activator-severe combined immunodeficiency mice (uPA(+/+)-SCID mice) given transplants of human hepatocytes (humanized livers).
Antibodies against HCV envelope proteins were detected in the sera of immunized mice; these sera inhibited infection of cultured cells with HCV genotypes 1a, 1b, and 2a. Immunoglobulin G purified from the sera of HCV-particle-immunized mice (iHCV-IgG) inhibited HCV infection of cultured cells. Injection of IgG from the immunized mice into uPA(+/+)-SCID mice with humanized livers prevented infection with the minimum infectious dose of HCV.
Inactivated HCV particles derived from cultured cells protect chimeric liver uPA(+/+)-SCID mice against HCV infection, and might be used in the development of a prophylactic vaccine.
丙型肝炎病毒(HCV)感染是肝癌的主要病因,因此需要采取预防感染的策略。最近已经建立了一种用于培养感染性 HCV 颗粒(HCVcc)的细胞培养系统;失活的 HCVcc 颗粒可能被用作疫苗开发中的抗原。我们旨在确认 HCVcc 作为 HCV 颗粒疫苗的潜力。
通过超滤和超速离心纯化步骤从培养的细胞中纯化来自 J6/JFH-1 嵌合基因组的 HCVcc。纯化的 HCV 颗粒经失活后与佐剂一起注入雌性 BALB/c 小鼠。采集免疫小鼠的血清,并在未感染的 Huh7.5.1 细胞和接受人肝细胞移植的尿激酶型纤溶酶原激活物-严重联合免疫缺陷小鼠(uPA(+/+)-SCID 小鼠)中检测其中和 HCV 的能力。
在免疫小鼠的血清中检测到针对 HCV 包膜蛋白的抗体;这些血清抑制了 HCV 基因型 1a、1b 和 2a 培养细胞的感染。从 HCV 颗粒免疫小鼠的血清中纯化的免疫球蛋白 G(iHCV-IgG)抑制了培养细胞中的 HCV 感染。将免疫小鼠的 IgG 注射到具有人源化肝脏的 uPA(+/+)-SCID 小鼠中,可防止感染最小感染剂量的 HCV。
来自培养细胞的失活 HCV 颗粒可保护嵌合肝脏 uPA(+/+)-SCID 小鼠免受 HCV 感染,可能被用于开发预防性疫苗。